{"nctId":"NCT00078767","briefTitle":"Pharmacologic Treatment of PTSD in Sexually Abused Children","startDateStruct":{"date":"2001-04"},"conditions":["Stress Disorders, Post-Traumatic"],"count":24,"armGroups":[{"label":"TF-CBT + sertraline","type":"EXPERIMENTAL","interventionNames":["Behavioral: Trauma-Focused Cognitive Behavioral Therapy","Drug: Sertraline Pill"]},{"label":"TF-CBT +placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sertraline Pill","Drug: Placebo Oral Tablet"]}],"interventions":[{"name":"Trauma-Focused Cognitive Behavioral Therapy","otherNames":[]},{"name":"Sertraline Pill","otherNames":[]},{"name":"Placebo Oral Tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion:\n\n1. Ages 10-17 years, inclusive\n2. Confirmed sexual abuse\n3. At least 5 PTSD symptoms on KSADS-PL, with at least one symptom in each of 3 symptom clusters (reexperiencing, avoidance, arousal)\n4. Parent/primary caregiver available to participate in treatment\n5. Assent with parental consent to participate\n\nExclusion:\n\n1. Non-English speaking\n2. schizophrenia or other severe psychotic disorder\n3. MR (IQ\\<60) or PDD preventing CBT treatment\n4. taking current psychotropic medication\n5. documented substance dependence (substance abuse allowed)","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Kiddie-Sads-Present and Lifetime (KSADS-PL) Scale for PTSD","description":"Change in PTSD parameters as determined by changes in score. At enrollment, participants either did or did not have a PTSD diagnosis. The three categories displayed show participants who had the PTSD diagnosis at the time of enrollment but did have evidence of PTSD at the end of their participation, participants who had PTSD at enrollment and who continued to exhibit PTSD at the end of their participation, and those who did not have a PTSD diagnosis at the start of the trial. There are numerous criteria used to determine a PTSD diagnosis; they are not individually listed. The diagnosis was sufficient for the purposes of the study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mood and Feelings Questionnaire (MFQ) for Depressive Symptoms","description":"Change in depressive symptoms as determined by change in score","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Anxiety Symptoms","description":"Change in SCARED scores between treatment groups.There were two categories of depression: participants that had clinical signs of depression at the time of enrollment, and participants that did not have clinical signs of depression. Participants in the \"clinical symptom present at enrollment\" category were tested to see if their status changed during the trial.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Impairment","description":"Change in Children's Global Assessment Scale (CGAS) between the two groups","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Suicidality","description":"Change in degree of suicidal ideation during study","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":[]}}}